文献リスト

1）Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007; 369: 1287-301

2）Harris PC, Torres, VE. Polycystic kidney disease. Annu Rev Med. 2009;60: 321-37

3）Pirson Y. Extrarenal manifestations of autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010; 17: 173-80

4）Fick GM, Gabow PA. Natural history of autosomal dominant polycystic kidney disease. Annu Rev Med. 1994; 45: 23-9

5）Pirson Y, Chauveau D, Torres V. Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2002; 13: 269-76

6）Kumar S, Adeva M, King BF, et al. Duodenal diverticulosis in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2006; 21: 3576-8

7）Pirson Y. Extrarenal manifestations of autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010; 17: 173-80

8）「エビデンスに基づく多発性嚢胞腎診療ガイドライン2014」日本腎臓学会誌. 2014; 56: 1105-87

9）花岡一成. 常染色体優性多発性嚢胞腎の遺伝子診断. 腎と透析. 2014; 77: 729-34

10）European Polycystic Kidney Disease Consortium. The polycystic kidney disease1 gene encodes a 14kb transcript and lies within a duplicated region on chromosome 16. Cell. 1994; 77: 881-94

11）Hughes J, Ward CJ, Peral B, et al. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet. 1995; 10: 151-60

12）Mochizuki T, Wu G, Hayashi T, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science. 1996; 271: 1339-42

13）Veldhuisen B, Saris JJ, de Haij S, et al. A spectrum of mutations in the second gene for autosomal dominant polycystic kidney disease (PKD2). Am J Hum Genet. 1997; 61: 547-55

14）Qian F, Germino FJ, Cai Y, et al. PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet. 1997; 16: 179-83

15）Tsiokas L, Kim E, Arnould T, et al. Homo-and heterodimeric interactions between the gene products of PKD1 and PKD2. Proc Natl Acad Sci U S A. 1997; 94: 6965-70.

16）Hanaoka K, Qian F, Boletta A, et al. Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature. 2000; 408: 990-4

17）Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol. 2002; 13: 2508-16

18）Nauli SM, Alenghat FJ, Luo Y, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet. 2003; 33: 129-37

19）Sharif-Naeini R, Folgering JH, Bichet D, et al. Polycystin-1 and -2 dosage regulates pressure sensing. Cell. 2009; 139: 587-96

20）Harris PC, Torres VE. Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest. 2014; 124: 2315-24

21）Torra R, Badenas C, Damell A, et al. Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease type 1 and 2. J Am Soc Nephrol. 1996; 7: 2142-51

22）Gall EC, Audrezet MP, Chen JM, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013; 24: 1006-13

23）Bogdanova N, Dworniczak B, Dragova D, et al. Genetic heterogeneity of polycystic kidney disease in Bulgaria. Hum Genet. 1995; 95: 645-50

24）Daoust MC, Reynolds DM, Bichet DG, et al. Evidence for a third genetic locus for autosomal dominant polycystic kidney disease. Genomics. 1995; 25: 733-6

25）Ariza M, Alvarez V, Marín R, et al. A family with a milder form of adult dominant polycystic kidney disease not linked to the PKD1 (16p) or PKD2 (4q) genes. J Med Genet. 1997; 34: 587-9

26）Paul BM, Consugar MB, Ryan Lee M, et al. Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families. Kidney Int. 2014; 85: 383-92

27）Peral B, Ward CJ, San Millán JL, et al. Evidence of linkage disequilibrium in the Spanish polycystic kidney disease I population. Am J Hum Genet. 1994; 54: 899-908

28）Peters DJ, Spruit L, Saris JJ, et al. Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease. Nat Genet. 1993; 5: 359-62

29）Reed B, McFann K, Kimberling WJ, et al. Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. Am J Kidney Dis. 2008; 52: 1042-50

30）Connor A, Lunt PW, Dolling C, et al. Mosaicism in autosomal dominant polycystic kidney disease revealed by genetic testing to enable living related renal transplantation. Am J Transplant. 2008; 8: 232-7

31）Rossetti S, Kubly VJ, Consugar MB, et al. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int. 2009; 75: 848-55

32）Zhao X, Paterson AD, Zahirieh A, et al. Molecular diagnostics in autosomal dominant polycystic kidney disease: utility and limitations. Clin J Am Soc Nephrol. 2007; 3: 146-52

33）Rossetti S, Consugar MB, Chapman AB, et al. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2007; 18: 2143-60

34）Garcia-Gonzalez MA, Jones JG, Allen SK, et al. Evaluating the clinical utility of a molecular genetic test for polycystic kidney disease. Mol Genet Metab. 2007; 92: 160-7

35）Harris PC, Rossetti S. Molecular diagnostics autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2010; 6: 197-206

36）Loftus BJ, Kim UJ, Sneddon VP, et al. Genome duplications and other features in 12 Mb of DNA sequence from human chromosome 16p and 16q. Genomics. 1999; 60: 295-308

37）Martin J, Han C, Gordon LA, et al. The sequence and analysis of duplication-rich human chromosome 16. Nature. 2004; 432: 988-94

38）Phakdeekitcharoen B, Watnick TJ, Germino GG. Mutation analysis of the entire replicated portion of PKD1 using genomic DNA samples. J Am Soc Nephrol. 2001; 12: 955-63

39）Consugar MB, Wong WC, Lundquist PA, et al. Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int. 2008; 74: 1468-79

40）Brook-Carter PT, Peral B, Ward CJ, et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease--a contiguous gene syndrome. Nat Genet. 1994; 8: 328-32

41）Barua M, Cil O, Paterson AD, et al. Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol. 2009; 20: 1833-8

42）Audrézet MP, Cornec-Le Gall E, Chen JM, et al. Autosomal dominant polycystic kidney disease: comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients. Hum Mutat. 2012; 33: 1239-50

43）Kurashige M, Hanaoka K, Imamura M, et al. A comprehensive search for mutations in the PKD1 and PKD2 in Japanese subjects with autosomal dominant polycystic kidney disease. Clin Genet (on line)3 April 2014; DOI : 10.1111/cge.12372 [Epub ahead of print]

44）Gout AM, Martin NC, Brown AF, et al. PKDB: Polycystic kidney disease mutation database--a gene variant database for autosomal dominant polycystic kidney disease. Hum Mutat. 2007; 28: 654-9

45）Tan YC, Michaeel A, Blumenfeld J, et al. A novel long-range PCR sequencing method for genetic analysis of the entire PKD1 gene. J Mol Diagn. 2012; 14: 305-13

46）Rossetti S, Hopp K, Sikkink RA, et al. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol. 2012; 23: 915-33

47）Tan AY, Michaeel A, Liu G, at al. Molecular diagnosis of autosomal dominant polycystic kidney disease using next-generation sequencing. J Mol Diagn. 2014; 16: 216-28

48）Yang T, Meng Y, Wei X, at al. Identification of novel mutations of PKD1 gene in Chinese patients with autosomal dominant polycystic kidney disease by targeted next-generation sequencing. Clin Chim Acta. 2014; 433: 12-9

49）Garcia-Gonzalez MA, Jones JG, Allen SK, et al. Evaluating the clinical utility of a molecular genetic test for polycystic kidney disease. Mol Genet Metab. 2007; 92: 160-7

50）Zhao X, Paterson AD, Zahirieh A, et al. Molecular diagnostics in autosomal dominant polycystic kidney disease: utility and limitations. Clin J Am Soc Nephrol. 2008; 3: 146-52

51）Kanaan N, Devuyst O, Pirson Y. Renal transplantation in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2014; 10: 455-65

52）Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol. 2014; 25: 18-32

53）Devuyst O, Torres VE. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease. Curr Opin Nephrol Hypertens. 2013; 22: 459-70

54）Hanaoka K, Guggino WB. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol. 2000; 11: 1179-87

55）Yamaguchi T, Pelling JC, Ramaswamy NT, et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int. 2000; 57: 1460-71

56）Hanaoka K, Devuyst O, Schwiebert EM, et al. A role for CFTR in human autosomal dominant polycystic kidney disease. Am J Physiol. 1996; 270: C389-99

57）Torres VE. Role of vasopressin antagonists. Clin J Am Soc Nephrol. 2008; 3: 1212-8

58）Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008; 371: 1624-32

59）Gattone VH 2nd, Wang X, Harris PC, et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003; 9: 1323-6

60）Wang X, Gattone V 2nd, Harris PC, et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol. 2005; 16: 846-51

61）Gattone VH 2nd, Wang X, Harris PC. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003; 9: 1323-6

62）Torres VE, Wang X, Qian Q, et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004; 10: 363-4

63）Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012; 367: 2407-18

64）Rahbari-Oskoui F, Williams O, Chapman A. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014; 29: 2194-201

65）Tkachenko O, Helal I, Shchekochikhin D, et al. Renin-angiotensin-aldosterone system in autosomal dominant polycystic kidney disease. Curr Hypertens Rev. 2013; 9: 12-20

66）Cadnapaphornchai MA, McFann K, Strain JD, et al. Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol. 2009; 4: 820-9

67）Jafar TH, Stark PC, Schmid CH, et al. The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int. 2005; 67: 265-71

68）van Dijk MA, Breuning MH, Duiser R, et al. No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2003; 18: 2314-20

69）Nutahara K, Higashihara E, Horie S, et al. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract. 2005; 99: c18-23

70）Mitobe M, Yoshida T, Sugiura H, et al. Clinical effects of calcium channel blockers and renin-angiotensin-aldosterone system inhibitors on changes in the estimated glomerular filtration rate in patients with polycystic kidney disease. Clin Exp Nephrol. 2010; 14: 573-77

71）Ecder T, Edelstein CL, Fick-Brosnahan GM, et al. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol. 2001; 21: 98-103

72）Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med. 2005; 142: 342-51

73）Locatelli F, Alberti D, Graziani G, et al. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet. 1991; 337: 1299-304

74）Klahr S, Breyer JA, Beck GJ, et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol. 1995; 5: 2037-47

75）Levey AS, Greene T, Sarnak MJ, et al. Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis. 2006; 48: 879-88

76）Wang CJ, Creed C, Winklhofer FT, et al. Water prescription in autosomal dominant polycystic kidney disease: a pilot study. Clin J Am Soc Nephrol. 2011; 6: 192-7

77）日本医学会「医療における遺伝学的検査・診断に関するガイドライン」(2011年2月)

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp